Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:

Frequency and severity of local injection site reactogenicity signs and symptoms [ Time Frame: Measured for 3 days following each vaccination visit (Days 0, 28, 84, and 168) ] [ Designated as safety issue: Yes ]

Local injection site signs and symptoms may include pain, tenderness, erythema, induration, and maximum severity of pain and/or tenderness.

Number of participants with early discontinuation of vaccinations and reason for discontinuation [ Time Frame: Measured through Day 364 visit ] [ Designated as safety issue: No ]

Breadth of the T-cell response determined as the number of reactive CD4 and CD8 T-cell epitopes using global potential T-cell epitope (PTEg) peptides [ Time Frame: Measured through Day 182 visit ] [ Designated as safety issue: No ]

Breadth of the T-cell response determined as the number of reactive CD4 and CD8 T-cell epitopes to PTEg and Center for HIV/AIDS Vaccine Immunology (CHAVI) peptide set [ Time Frame: Measured through Day 182 visit ] [ Designated as safety issue: No ]

Total magnitude of CD4 and CD8 T-cell responses measured by ICS to PTEg [ Time Frame: Measured through Day 182 visit ] [ Designated as safety issue: No ]

Depth of the T-cell responses, determined as the variant recognition per epitope targeted by responding T cells using PTEg and CHAVI peptides [ Time Frame: Measured through Day 182 visit ] [ Designated as safety issue: No ]

Response rate of CD4 and CD8 T-cell responses to PTEg and CHAVI peptide sets measured by ICS [ Time Frame: Measured through Day 182 visit ] [ Designated as safety issue: No ]

Magnitude and breadth of serum neutralizing antibodies (nAbs) to a panel of standardized HIV-1 isolates [ Time Frame: Measured through Day 364 visit ] [ Designated as safety issue: No ]

All three DNA env vaccines will be administered IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated) using the Biojector 2000® device.

Placebo Comparator: Group 3: placebo vaccines with Mosaic env insert

Participants in this arm will receive placebo injections of DNA Mosaic env vaccine on Day 0 and Day 28 followed by placebo injections for NYVAC Mosaic env vaccine on Day 84 and Day 164.

Biological: Placebo

Placebo for both DNA and NYVAC vaccines will be administered in the deltoid muscle of the non-dominant arm (unless medically contraindicated) as sodium chloride for injection, 0.9%.

Detailed Description:

The purpose of this study is to evaluate the safety, tolerability, and immune response to three different HIV-1 prime-boost vaccine regimens in healthy, HIV-1-uninfected adults. The regimens will differ by the type of HIV-1 envelope insert (Nat-B env, CON-S env, or Mosaic env) contained in both the DNA prime vaccine and the NYVAC boost vaccine.

The study will enroll 180 healthy, HIV-1-uninfected adults in two stages (Part A and Part B). After Part A of the study is fully enrolled, study researchers will evaluate study immunogenicity data to determine whether to enroll participants into Part B. The study design and vaccination schedule for both parts of the study will be the same.

Participants will be randomly assigned to one of three groups and receive either one of the experimental vaccine regimens or a placebo vaccine regimen. Participants will receive four total injections: on Day 0 and Day 28 (DNA vaccine or placebo) and on Day 84 and Day 168 (NYVAC vaccine or placebo). Group 1 participants will receive DNA Nat-B env and NYVAC Nat-B env vaccines, Group 2 participants will receive DNA CON-S env and NYVAC CON-S env vaccines, and Group 3 participants will receive DNA Mosaic env and NYVAC Mosaic env vaccines.

Total study duration will be either 3 years after enrollment (for participants in the United States) or 5 years after enrollment (for participants in Switzerland). For all participants, study visits will occur on Days 0, 14, 28, 42, 84, 98, 168, 175, 182, 273, 357, and 364. After the last study visit, participants will be contacted annually by phone or e-mail for a total of 3 (U.S. participants) or 5 (Switzerland participants) years to answer questions about their health.

At screening, participants will give a medical history; undergo a complete physical exam, blood collection, urine collection, and an electrocardiogram (ECG); and receive risk reduction counseling. At most follow-up visits, participants will undergo an abbreviated physical exam, blood collection, urine collection, and receive risk reduction counseling. Participants will have additional ECGs on Days 98 and 182. At all visits, female participants who were born female will be assessed for pregnancy prevention, and at select visits, will undergo a pregnancy test.

Eligibility

Ages Eligible for Study:

18 Years to 50 Years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

Yes

Criteria

Inclusion Criteria:

Access to a participating HIV Vaccine Trials Network (HVTN) clinical research site (CRS) and willingness to be followed for the planned duration of the study

Ability and willingness to provide informed consent

Assessment of understanding: participant demonstrates understanding of this study; completes a questionnaire prior to first vaccination with verbal demonstration of understanding of all questionnaire items answered incorrectly

Willing to be contacted annually after completion of scheduled clinic visits for a total of 3 years for U.S. participants (5 years for participants in Switzerland) following initial study injection

Agrees not to enroll in another study of an investigational research agent

Good general health as shown by medical history, physical exam, and screening laboratory tests

Hemoglobin greater than or equal to 12.5 g/dL for participants who were born female, or greater than or equal to 13.5 g/dL for participants who were born male

White blood cell count equal to 3,300 to 12,000 cells/mm^3

Total lymphocyte count greater than or equal to 800 cells/mm^3

Remaining differential either within institutional normal range or with site physician approval

Platelets equal to 125,000 to 550,000/mm^3

Chemistry panel: ALT, AST, and alkaline phosphatase less than 1.25 times the institutional upper limit of normal (ULN); creatinine less than or equal to ULN

Cardiac Troponin T or I (cTnT or cTnI) does not exceed the institutional ULN

Negative HIV-1 and -2 blood test: U.S. participants must have a negative Food and Drug Administration (FDA)-approved enzyme immunoassay. Non-U.S. sites may use locally available assays that have been approved by HVTN Laboratory Operations.

Participants who were born female: negative serum or urine beta human chorionic gonadotropin (β-HCG) pregnancy test performed prior to vaccination on the day of initial vaccination

Reproductive status: A participant who was born female must agree to consistently use effective contraception for sexual activity that could lead to pregnancy from at least 21 days prior to enrollment through the last required protocol clinic visit. More information on this criterion can be found in the protocol.

Participants who were born female must also agree not to seek pregnancy through alternative methods, such as artificial insemination or in vitro fertilization until after the last required protocol clinic visit

Exclusion Criteria:

Blood products received within 120 days before first vaccination

Investigational research agents received within 30 days before first vaccination

Body mass index (BMI) greater than or equal to 40; less than or equal to 18; or greater than or equal to 35 with 2 or more of the following: age greater than 45, systolic blood pressure greater than 140 mm Hg, diastolic blood pressure greater than 90 mm Hg, current smoker, or known hyperlipidemia

Intent to participate in another study of an investigational research agent during the planned duration of this study

Pregnant or breastfeeding

HIV vaccine(s) received in a prior HIV vaccine trial. For participants who have received control/placebo in an HIV vaccine trial, the HVTN 099 Protocol Safety Review Team (PSRT) will determine eligibility on a case-by-case basis and the identity of the study control/placebo must be obtained.

Non-HIV experimental vaccine(s) received within the last 5 years in a prior vaccine trial. Exceptions may be made for vaccines that have subsequently undergone licensure by the FDA. For volunteers who have received control/placebo in an experimental vaccine trial, the HVTN 099 PSRT will determine eligibility on a case-by-case basis. For volunteers who have received an experimental vaccine(s) greater than 5 years ago, eligibility for enrollment will be determined by the HVTN 099 PSRT on a case-by-case basis.

Live attenuated vaccines other than influenza vaccine received within 30 days before first vaccination or scheduled within 14 days after injection (e.g., measles, mumps, and rubella [MMR]; oral polio vaccine [OPV]; varicella; yellow fever)

Influenza vaccine or any vaccines that are not live attenuated vaccines and were received within 14 days prior to first vaccination (e.g., tetanus, pneumococcal, hepatitis A or B)

Allergy treatment with antigen injections within 30 days before first vaccination or that are scheduled within 14 days after first vaccination

Immunosuppressive medications received within 168 days before first vaccination. (Not excluded: [1] corticosteroid nasal spray; [2] inhaled corticosteroids; [3] topical corticosteroids for mild, uncomplicated dermatitis; or [4] a single course of oral/parenteral corticosteroids at doses less than 2 mg/kg/day and length of therapy less than 11 days with completion at least 30 days prior to enrollment.)

Serious adverse reactions to vaccines including anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain. (Not excluded: a participant who had a nonanaphylactic adverse reaction to pertussis vaccine as a child.)

Immunoglobulin received within 60 days before first vaccination

Autoimmune disease

Immunodeficiency

Hypersensitivity to eggs and/or egg products

Untreated or incompletely treated syphilis infection

Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health. More information on this criterion can be found in the protocol.

Any medical, psychiatric, occupational, or other condition that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety or reactogenicity, or a volunteer's ability to give informed consent

Psychiatric condition that precludes compliance with the protocol. Specifically excluded are persons with psychoses within the past 3 years, ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years.

Current anti-tuberculosis prophylaxis or therapy

Asthma other than mild, well-controlled asthma. More information on this criterion can be found in the protocol.

Thyroidectomy, or thyroid disease requiring medication during the last 12 months

Hypertension: If a participant has been found to have elevated blood pressure or hypertension during screening or previously, exclude for blood pressure that is not well controlled (as defined in the protocol). If a person has NOT been found to have elevated blood pressure or hypertension during screening or previously, exclude for systolic blood pressure greater than or equal to 150 mm Hg at enrollment or diastolic blood pressure greater than or equal to 100 mm Hg at enrollment. More information on this criterion can be found in the protocol.

Participants who have 2 or more of the following cardiac risk factors: participant report of history of elevated blood cholesterol defined as fasting LDL greater than 160 mg/dL; first degree relative (e.g., mother, father, brother, or sister) who had coronary artery disease before the age of 50 years; current smoker; or BMI greater than or equal to 35

ECG with clinically significant findings or features that would interfere with the assessment of myo/pericarditis, as determined by the contract ECG Lab, cardiologist, or study clinician. More information on this criterion can be found in the protocol.

History of hereditary angioedema, acquired angioedema, or idiopathic angioedema

Malignancy (Not excluded: Participant who has had malignancy excised surgically and who, in the investigator's estimation, has a reasonable assurance of sustained cure or who is unlikely to experience recurrence of malignancy during the period of the study)

Seizure disorder: History of seizure(s) within past 3 years. Also exclude if volunteer has used medications in order to prevent or treat seizure(s) at any time within the past 3 years.

Asplenia: any condition resulting in the absence of a functional spleen

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01970449